 | • レポートコード：D0-MOR-AP0298 • 出版社/出版日：Mordor Intelligence / 2020年4月20日 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：健康管理 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、コルチコステロイドの世界市場について調査・分析した資料で、コルチコステロイドの市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。 |
The corticosteroids market is expected to witness a CAGR of 4.3%, during the forecast period (2020-2025). The major factors accounting for the growth of the corticosteroid market are increasing the incidence of chronic diseases, growing geriatric population and surging investment in research and development. According to the United Nations forecast human population is expected to increase from 7.2 billion today to 8.2 billion by 2025. This, in turn, increases the burden of chronic diseases to 57% worldwide according to WHO by the end of 2020 and is expected to increase further during the forecast period. Hence, this uninterrupted incidence and prevalence of chronic diseases lead to the growth of the Corticosteroids market during the forecast period. However, the risk factors associated with the prolonged use of corticosteroids hampers the growth of the market to some extent.
Key Market Trends
Topical Steroids segment by Route of Administration Dominates the Market
Topical steroids are used in treating the skin conditions such as rash, dermatitis, itching, eczema, and psoriasis and this segement is expected to dominate the market due to the continuous growth of the geriatric population with rising skin diseases around the world and the extended storage capacity of the topical corticosteroids. As aging results in the decline of the normal functioning of organ systems including skin, the geriatric population is highly prone to skin diseases. According to the data from World Population Prospects: the 2019 Revision, by 2050, one in six people in the world will be over age 65 (16%), up from one in 11 in 2019 (9%). In terms of convenience, the geriatric population with skin diseases prefers to use topical steroids. All these factors together support that Topical steroids dominate the corticosteroids market.
North America Dominates the Market and the Same is Expected Over the Forecast Period.
North America is expected to dominate the overall market, throughout the forecast period, which is attributed to the developed economy, increasing health care expenditure, increasing incidence of lifestyle-related diseases and high adoption of technologically advanced products in the region. According to National Cancer Institute statistics the incidence of cancer increased to 1.8 million in 2019 from 1.73 million in 2018, suggests the growth in chronic diseases burden in United States. Furthermore, according to the World Population Prospects: the 2019 Revision, one in four persons living in North America could be aged 65 or over by 2050 which strongly supports North America to dominate the market during the forecast period.
Competitive Landscape
The corticosteroids market is moderately competitive and consists of several major players. With the increasing consolidations of various organizations in the healthcare sector, it is expected to generate the competitive rivalry among the key players in future. Some of the major players of the market are Pfizer Inc., Novartis, AstraZeneca, GSK, Cipla Inc., and Merck etc.,
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Geriatric Population and Increasing Incidence of Chronic Diseases
4.2.2 Surging investment in Research and Development
4.3 Market Restraints
4.3.1 Pricing Pressure on the Companies by the Government
4.3.2 Risk factors associated with Corticosteriods on Prolonged use
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Glucocorticoids
5.1.2 Mineralocorticoids
5.2 By Route of administration
5.2.1 Topical steroids
5.2.2 Inhaled steroids
5.2.3 Oral forms
5.2.4 Systemic forms
5.2.5 Others
5.3 By Application
5.3.1 Rheumatology indications
5.3.2 Skin allergies
5.3.3 Endocrinology
5.3.4 Gastroenterology
5.3.5 Acute respiratory diseases
5.3.6 Others
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Novartis AG
6.1.3 Sanofi S.A.
6.1.4 GlaxoSmithKline plc
6.1.5 Cipla Inc.
6.1.6 Johnson & Johnson Services, Inc.
6.1.7 AstraZeneca plc
6.1.8 Merck & Co., Inc.,
6.1.9 Sumitomo Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS